ACCESSWIRE
11 May 2022, 21:13 GMT+10
Class 1 Medical Device Registration Allows Nutriband To Explore New Product Manufacturing Opportunities Through Its Wholly Owned Subsidiary Active Intelligence LLC
ORLANDO, FL / ACCESSWIRE / May 11, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced its Active Intelligence LLC subsidiary has registered as a Class I medical device manufacturer with the U.S. Food and Drug Administration (FDA) to manufacture and distribute its proprietary AI Tape, to compete in the growing kinesiology tape market.
'The FDA medical device manufacturing registration for Active Intelligence represents a pivotal milestone that paves the way for commercial sales of our AI Tape product in the United States,' commented Gareth Sheridan, CEO of Nutriband. 'The registration will enable Active Intelligence to manufacture AI Tape under its own brand or through white label agreements with sales and marketing partners as well as explore new opportunities for contract manufacturing in the medical device space. We look forward to providing the market with updates on the progress in the coming months.'
AI Tape is a kinesiology tape that is placed on the skin to support for athletes recovering from sports injuries. Active Intelligence is also developing a line of medicated kinesiology tapes to assist athletes in the recovery process after physical injury. The global sports medicine market exceeded $5 billion in 2021 and is projected to grow at a 6.8% CAGR through 2028, reaching an estimated $8.9 billion, according to data from Statista.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,'' 'anticipates,' 'expects' and words of similar import, constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's Form S-1, Form 10-K for the year ended January 31, 2020 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
Investor Relations
RedChip Companies
Dave Gentry
NTRB@redchip.com
1-800-RED-CHIP (733-2447)
407-491-4498
SOURCE: Nutriband Inc.
Get a daily dose of Boston Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Boston Star.
More InformationSANTIAGO, Chile: Easter Island, one of Chile's most important tourist attractions, will reopen to visitors on August 1, the government ...
NEW DEHLI, India: In a move expected to end the country's exports of the raw materials needed to manufacture steel, ...
NEW YORK, New York - The release of the minutes of the Federal Reserve's monetary meeting earlier this month surprisingly ...
WASHINGTON D.C.: A leading U.S. official has said that even if Taiwan is excluded from President Joe Biden's Asian economic ...
MOSCOW, Russia: In the latest escalation of an energy payment dispute with Western nations, Russia's Gazprom has halted gas exports ...
SYDNEY, NSW, Australia - It was a lukewarm day for stocks across Asia Wednesday with little movement in either direction.In ...
Jake Burger launched a go-ahead, three-run home run in the fifth inning and Lucas Giolito pitched six innings of one-run ...
Jaylen Brown scored 25 points and Jayson Tatum added 22 points and 12 rebounds as the visiting Boston Celtics moved ...
It will be the Miami Heat's chance to turn the tables in the Eastern Conference finals when they play host ...
Veteran center Joe Thornton saw the Florida Panthers' season come to an abrupt end earlier this week. Thornton, however, wasn't ...
T1 announced the signing Wednesday of Sang-beom "Munchkin" Byeon to their evolving Valorant roster. The 24-year-old South Korean previously competed ...
Tuesday's 16-run barrage against the Chicago White Sox gave the Boston Red Sox 95 runs in their past 13 games. ...